NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Taizhou Baiying Biotechnology

Taizhou Baiying Biotechnology

Private
Shanghai, ShanghaiHealthcare & Life Scienceshttps://www.biointron.com

Last Round

Series B

Sep 2, 2022

Total Funding Raised

$92.05M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Biointron is a biotechnology company specializing in recombinant antibody technology and contract research organization (CRO) services aimed at streamlining the antibody discovery process through advanced expression platforms, sequencing, and labeling tools.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract research organizationCROrecombinant antibody expressionantibody discoveryprotein expressionantibody engineeringdrug discovery serviceswet-lab servicesstable cell line developmentbiologics developmentantibody humanizationaffinity maturationVHH antibody discoveryantibody-drug conjugateADCsingle B-cell screeninghybridoma sequencing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Taizhou Baiying Biotechnology Comparables

Compare Taizhou Baiying Biotechnology with similar companies based on industry and business-model similarity.

Taizhou Baiying Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Creative Biolabs
85%
Genovac Antibody Discovery
82%
ProteoGenix
82%

Taizhou Baiying Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 2, 2022
Series AMay 24, 2021
AngelJul 23, 2018

Taizhou Baiying Biotechnology Investors

Notable investors and investment history

Taizhou Baiying Biotechnology investors
InvestorRounds
Jifeng VenturesSeries B
Haitong BankSeries B
Joy CapitalSeries B
Jiangsu Provincial Government Investment FundSeries B
Furong InvestmentSeries A
ALAN Asset ManagementSeries B
Jiangsu Tianyou Investment ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    New platform helps drug developers identify manufacturing problems early.

  • Dec 17, 2025

    Received the 2025 Scientist.com Supplier Performance Recognition Award.

Taizhou Baiying Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Taizhou Baiying Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Taizhou Baiying Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai, Shanghai
Employee Range41
Year Founded2012
Last FundingSep 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.